WO1996004915A1 - Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes - Google Patents

Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes Download PDF

Info

Publication number
WO1996004915A1
WO1996004915A1 PCT/US1995/010110 US9510110W WO9604915A1 WO 1996004915 A1 WO1996004915 A1 WO 1996004915A1 US 9510110 W US9510110 W US 9510110W WO 9604915 A1 WO9604915 A1 WO 9604915A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
hydrogen
lower alkyl
carbon atoms
compound
Prior art date
Application number
PCT/US1995/010110
Other languages
English (en)
Other versions
WO1996004915A9 (fr
Inventor
Peter Davies
Inez J. Vincent
Original Assignee
Albert Einstein College Of Medicine Of Yeshiva University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine Of Yeshiva University filed Critical Albert Einstein College Of Medicine Of Yeshiva University
Priority to EP95929441A priority Critical patent/EP0778773A1/fr
Priority to AU32793/95A priority patent/AU708682B2/en
Priority to JP8507474A priority patent/JPH11506414A/ja
Publication of WO1996004915A1 publication Critical patent/WO1996004915A1/fr
Publication of WO1996004915A9 publication Critical patent/WO1996004915A9/fr
Priority to KR1019970700943A priority patent/KR970704445A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Abstract

On décrit des procédés qui permettent de prévenir ou traiter la maladie d'Alzheimer et consistent à administrer à un patient une quantité d'une phénothiazine ou d'un thioxanthène efficace pour prévenir ou diminuer l'accumulation d'épitopes anormalement phosphorylés, à filaments hélicoïdaux appariés, qui sont associés à la maladie d'Alzheimer.
PCT/US1995/010110 1994-08-08 1995-08-07 Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes WO1996004915A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP95929441A EP0778773A1 (fr) 1994-08-08 1995-08-07 Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes
AU32793/95A AU708682B2 (en) 1994-08-08 1995-08-07 Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
JP8507474A JPH11506414A (ja) 1994-11-30 1995-08-07 フェノチアジン類および／またはチオキサンテン類を用いてアルツハイマー病を治療および／または予防する方法
KR1019970700943A KR970704445A (ko) 1994-08-08 1997-02-10 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28733994A 1994-08-08 1994-08-08
US08/287,339 1994-08-08
US34675794A 1994-11-30 1994-11-30
US08/346,757 1994-11-30

Publications (2)

Publication Number Publication Date
WO1996004915A1 true WO1996004915A1 (fr) 1996-02-22
WO1996004915A9 WO1996004915A9 (fr) 1996-04-11

Family

ID=26964404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/010110 WO1996004915A1 (fr) 1994-08-08 1995-08-07 Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes

Country Status (5)

Country Link
EP (1) EP0778773A1 (fr)
KR (1) KR970704445A (fr)
AU (1) AU708682B2 (fr)
CA (1) CA2196529A1 (fr)
WO (1) WO1996004915A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030766A1 (fr) * 1995-03-27 1996-10-03 F. Hoffmann-La Roche Ag Inhibition de l'association tau-tau
WO1999000115A1 (fr) * 1997-06-27 1999-01-07 Smithkline Beecham Plc Utilisation d'antagonistes ou d'agonistes partiels des complexes recepteurs du vanilloïde pour le traitement de maladies neurodegeneratives
DE19842416A1 (de) * 1998-09-16 2000-04-13 Max Planck Gesellschaft Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden
WO2002003972A2 (fr) * 2000-07-11 2002-01-17 Hunter-Fleming Limited Utilisation therapeutique et prophylactique de formes reduites de composes pharmaceutiques
WO2002075318A3 (fr) * 2001-03-20 2004-03-11 Univ Aberdeen Marqueurs neurofibrillaires
EP1470818A1 (fr) * 2003-04-25 2004-10-27 Neuro3D Utilisation de dérivés de phénothiazine pipérazine pour la préparation d'un médicament ayant des effets neuroprotecteurs et/ou neurotrophiques sur le SNC et/ou SNP
WO2007110630A1 (fr) 2006-03-29 2007-10-04 Wista Laboratories Ltd. Composés de thioninium et utilisation
US7335505B2 (en) 2001-01-15 2008-02-26 Wista Laboratories Ltd. Materials and methods relating to protein aggregation in neurodegenerative disease
WO2008092898A1 (fr) * 2007-02-01 2008-08-07 Pad Pharma Limited Traitement de maladies d'agrégation de protéines
US7605179B2 (en) 2001-07-16 2009-10-20 Wista Laboratories Ltd. Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
ES2331282A1 (es) * 2008-06-25 2009-12-28 Consejo Superior De Investigaciones Cientificas (Csic) (45%) Hidrazidas de sistemas heterociclicos y su uso en el tratamiento de enfermedades neurodegenerativas.
US7737138B2 (en) 2004-09-23 2010-06-15 Wista Laboratories Ltd. Methods of treatment of a tauopathy condition comprising the use of thioninium compounds
US7834237B2 (en) 2001-01-03 2010-11-16 Wista Laboratories Ltd. Materials and methods relating to protein aggregation in neurodegenerative disease
US7888350B2 (en) 2006-03-29 2011-02-15 Wista Laboratories Ltd. 3,7-diamino-10H-phenothiazine salts and their use
DE102010062810A1 (de) * 2010-09-07 2012-03-08 Universität Rostock 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen
US8263589B2 (en) 2006-03-29 2012-09-11 Wista Laboratories Ltd. Inhibitors of protein aggregation
US20120329789A1 (en) * 2011-06-01 2012-12-27 Wisconsin Alumni Research Foundation Compositions and methods for treating alzheimers disease
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US10864216B2 (en) 2011-02-11 2020-12-15 Wista Laboratories, Ltd. Phenothiazine diaminium salts and their use
WO2022098106A1 (fr) * 2020-11-04 2022-05-12 주식회사 오에이티씨 Composition pour la prévention ou le traitement de maladies neuro-inflammatoires, comprenant de la chlorpromazine
WO2022104070A3 (fr) * 2020-11-13 2022-06-23 Icahn School Of Medicine At Mount Sinai Composés de phénothiazine pour le traitement de la maladie d'alzheimer et d'autres maladies neurologiques et liées à l'âge
WO2023131606A1 (fr) * 2022-01-04 2023-07-13 Immungenetics Ag Dosage spécifique de composés de phénothiazine destinés à être utilisés dans le traitement ou la prévention de la maladie d'alzheimer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837518A (en) * 1958-06-03 Phenthiazine compounds
US2902484A (en) * 1954-04-27 1959-09-01 Rhone Poulenc Sa Phenthiazine derivatives and processes for their preparation
NL108827C (fr) * 1956-04-09

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.J. ANDERSON ET AL.: "Increased immunoreactivity for Jun- and Fos-related proteins in alzheimer's disease: association with pathology.", EXP. NEUROL., vol. 125, no. 2, pages 286 - 295 *
C. RYMES-BARLEY ET AL.: "Alzheimer's disease- are drugs really effective?", ON CONTINUING PRACTICE, vol. 12, no. 2, pages 11 - 13 *
W.G. ERWIN ET AL.: "Treatment of Alzheimer's disease.", AM. DRUG., vol. 202, no. 3, pages 78 - 88 *

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1067386A3 (fr) * 1995-03-27 2004-11-24 The University Court of The University of Aberdeen Inhibition de l'association Tau-Tau
WO1996030766A1 (fr) * 1995-03-27 1996-10-03 F. Hoffmann-La Roche Ag Inhibition de l'association tau-tau
US6376205B1 (en) 1995-03-27 2002-04-23 University Court Of The University Of Aberdeen Screening methods for agents that modulate or inhibit tau association with tau or map2
US7534786B2 (en) 1995-03-27 2009-05-19 Wista Laboratories Ltd. Inhibition of tau-tau association
US8278298B2 (en) 1995-03-27 2012-10-02 Wista Laboratories Ltd. Inhibition of tau-tau-association
US6953794B2 (en) 1995-03-27 2005-10-11 The University Court Of The University Of Aberdeen Inhibition of tau-tau association
WO1999000115A1 (fr) * 1997-06-27 1999-01-07 Smithkline Beecham Plc Utilisation d'antagonistes ou d'agonistes partiels des complexes recepteurs du vanilloïde pour le traitement de maladies neurodegeneratives
DE19842416A1 (de) * 1998-09-16 2000-04-13 Max Planck Gesellschaft Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden
WO2002003972A3 (fr) * 2000-07-11 2002-10-24 Hunter Fleming Ltd Utilisation therapeutique et prophylactique de formes reduites de composes pharmaceutiques
WO2002003972A2 (fr) * 2000-07-11 2002-01-17 Hunter-Fleming Limited Utilisation therapeutique et prophylactique de formes reduites de composes pharmaceutiques
US7834237B2 (en) 2001-01-03 2010-11-16 Wista Laboratories Ltd. Materials and methods relating to protein aggregation in neurodegenerative disease
US7893054B2 (en) 2001-01-15 2011-02-22 Wista Laboratories Ltd. Materials and methods relating to protein aggregation in neurodegenerative disease
US7335505B2 (en) 2001-01-15 2008-02-26 Wista Laboratories Ltd. Materials and methods relating to protein aggregation in neurodegenerative disease
US7713962B2 (en) 2001-03-20 2010-05-11 Wista Laboratories Ltd. Neurofibrillary labels
US8097615B2 (en) 2001-03-20 2012-01-17 Wista Laboratories Ltd. Neurofibrillary labels
US7335652B2 (en) 2001-03-20 2008-02-26 Wista Laboratories Ltd. Neurofibrillary labels
WO2002075318A3 (fr) * 2001-03-20 2004-03-11 Univ Aberdeen Marqueurs neurofibrillaires
US7605179B2 (en) 2001-07-16 2009-10-20 Wista Laboratories Ltd. Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
WO2004096231A2 (fr) * 2003-04-25 2004-11-11 Neuro 3D Utilisation de derives de piperarizine phenothiazine, ou d'un sel ou ester de ceux-ci, dans la fabrication d'un medicament a effets neuroprotecteurs et/ou neurotrophiques sur le systeme nerveux central et/ou le systeme nerveux peripherique
EP1470818A1 (fr) * 2003-04-25 2004-10-27 Neuro3D Utilisation de dérivés de phénothiazine pipérazine pour la préparation d'un médicament ayant des effets neuroprotecteurs et/ou neurotrophiques sur le SNC et/ou SNP
WO2004096231A3 (fr) * 2003-04-25 2005-03-24 Neuro 3D Utilisation de derives de piperarizine phenothiazine, ou d'un sel ou ester de ceux-ci, dans la fabrication d'un medicament a effets neuroprotecteurs et/ou neurotrophiques sur le systeme nerveux central et/ou le systeme nerveux peripherique
US7737138B2 (en) 2004-09-23 2010-06-15 Wista Laboratories Ltd. Methods of treatment of a tauopathy condition comprising the use of thioninium compounds
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases
US8263589B2 (en) 2006-03-29 2012-09-11 Wista Laboratories Ltd. Inhibitors of protein aggregation
AU2007231127B2 (en) * 2006-03-29 2013-03-14 Wista Laboratories Ltd. Thioninium compounds and their use
US11951110B2 (en) 2006-03-29 2024-04-09 Wista Laboratories Ltd. 3, 7-diamino-10H-phenothiazine salts and their use
US11344558B2 (en) 2006-03-29 2022-05-31 Wista Laboratories Ltd. 3, 7-diamino-10H-phenothiazine salts and their use
US7888350B2 (en) 2006-03-29 2011-02-15 Wista Laboratories Ltd. 3,7-diamino-10H-phenothiazine salts and their use
US9174954B2 (en) 2006-03-29 2015-11-03 Wista Laboratories Ltd. 3,7-diamino-10H-phenothiazine salts and their use
EP2853293A1 (fr) * 2006-03-29 2015-04-01 WisTa Laboratories Ltd. Composés de thioninium et leur utilisation
WO2007110630A1 (fr) 2006-03-29 2007-10-04 Wista Laboratories Ltd. Composés de thioninium et utilisation
US8710051B2 (en) 2006-03-29 2014-04-29 Wis Ta Laboratories Ltd. 3,7-diamino-10H-phenothiazine salts and their use
US10238611B2 (en) 2006-10-12 2019-03-26 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US11020360B2 (en) 2006-10-12 2021-06-01 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US10857109B2 (en) 2006-10-12 2020-12-08 Bellus Health, Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
GB2458868B (en) * 2007-02-01 2011-04-06 Pad Pharma Ltd Fluphenazine based combination for use in the treatment of protein aggregation diseases
WO2008092898A1 (fr) * 2007-02-01 2008-08-07 Pad Pharma Limited Traitement de maladies d'agrégation de protéines
GB2458868A (en) * 2007-02-01 2009-10-07 Pad Pharma Ltd Treatment of protein aggregation diseases
US8383617B2 (en) 2007-02-01 2013-02-26 Pad Pharma Limited Treatment of protein aggregation diseases
WO2009156535A1 (fr) * 2008-06-25 2009-12-30 Consejo Superior De Investigaciones Científicas Hydrazides de systèmes hétérocycliques et leur utilisation dans le traitement des maladies neurodégénératives
ES2331282A1 (es) * 2008-06-25 2009-12-28 Consejo Superior De Investigaciones Cientificas (Csic) (45%) Hidrazidas de sistemas heterociclicos y su uso en el tratamiento de enfermedades neurodegenerativas.
CN106243060A (zh) * 2010-09-07 2016-12-21 免疫基因股份公司 2‑(R2‑硫代)‑10‑[3‑(4‑R1‑哌嗪‑1‑基)丙基]‑10H‑吩噻嗪用于治疗β‑淀粉样病或α‑共核蛋白病以及诊断或前诊断它们的方法
WO2012031941A3 (fr) * 2010-09-07 2012-09-20 Universität Rostock 2-(r²-thio)-10-[3-(4-r1-pipérazin-1-yl)propyl]-10h-phénothiazine pour le traitement d'une pathologie béta-amyloïde ou d'une alpha- synucléopathie, et procédé pour en faire le diagnostic ou le pré-diagnostic
CN103237802A (zh) * 2010-09-07 2013-08-07 免疫基因股份公司 2-(R2-硫代)-10-[3-(4-R1-哌嗪-1-基)丙基]-10H-吩噻嗪用于治疗β-淀粉样病或α-共核蛋白病以及诊断或前诊断它们的方法
DE102010062810A1 (de) * 2010-09-07 2012-03-08 Universität Rostock 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen
EP3097914A3 (fr) * 2010-09-07 2016-12-28 Immungenetics AG 2-(r²-thio)-10-[3-(4-r1-pipérazin-1-yl)propyl]-10h-phénothiazine pour le traitement d'une maladie neurodégénérative
CN103237802B (zh) * 2010-09-07 2017-06-09 免疫基因股份公司 2‑(R2‑硫代)‑10‑[3‑(4‑R1‑哌嗪‑1‑基)丙基]‑10H‑吩噻嗪用于治疗β‑淀粉样病或α‑共核蛋白病以及诊断或前诊断它们的方法
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
US9370523B2 (en) 2010-09-07 2016-06-21 Immungenetics Ag Method for diagnosing or prediagnosing a beta-amyloidopathy or an alpha-synucleopathy
US10864216B2 (en) 2011-02-11 2020-12-15 Wista Laboratories, Ltd. Phenothiazine diaminium salts and their use
US11180464B2 (en) 2011-02-11 2021-11-23 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
US8980884B2 (en) * 2011-06-01 2015-03-17 Wisconsin Alumni Research Foundation Methods for treating Alzheimer's disease
US9522124B2 (en) 2011-06-01 2016-12-20 Wisconsin Alumni Research Foundation Methods for treating Alzheimer's disease
US20120329789A1 (en) * 2011-06-01 2012-12-27 Wisconsin Alumni Research Foundation Compositions and methods for treating alzheimers disease
WO2022098106A1 (fr) * 2020-11-04 2022-05-12 주식회사 오에이티씨 Composition pour la prévention ou le traitement de maladies neuro-inflammatoires, comprenant de la chlorpromazine
WO2022104070A3 (fr) * 2020-11-13 2022-06-23 Icahn School Of Medicine At Mount Sinai Composés de phénothiazine pour le traitement de la maladie d'alzheimer et d'autres maladies neurologiques et liées à l'âge
WO2023131606A1 (fr) * 2022-01-04 2023-07-13 Immungenetics Ag Dosage spécifique de composés de phénothiazine destinés à être utilisés dans le traitement ou la prévention de la maladie d'alzheimer

Also Published As

Publication number Publication date
KR970704445A (ko) 1997-09-06
AU708682B2 (en) 1999-08-12
AU3279395A (en) 1996-03-07
CA2196529A1 (fr) 1996-02-22
EP0778773A1 (fr) 1997-06-18

Similar Documents

Publication Publication Date Title
AU708682B2 (en) Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
WO1996004915A9 (fr) Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes
EP2853293B1 (fr) Composés de thioninium et leur utilisation
Swartz et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors
CA2207333C (fr) Utilisation de nebivolol comme agent anti-atherogene
EP2373660B1 (fr) Sels de xanthylium 3,6-disubstitues comme medicaments
KR20070013265A (ko) 아세틸콜린에스테라아제 억제제 및(3ａＲ)-1,3ａ,8-트리메틸-1,2,3,3ａ,8,8ａ-헥사히드로피롤로[2,3-ｂ]인돌-5-일 페닐카르바메이트에 의한 조합 요법
US4855306A (en) Uses of dopamine receptor agonists
KR20070116900A (ko) 라이아노딘 수용체 (ｒｙｒ２)에서의 누출을 표적화하는신규한 항부정맥 및 심부전 약물
JP2008502602A (ja) タウオパシーの治療のための組成物および方法
US6228878B1 (en) Methods for treating or preventing alzheimer's disease using substituted 2-aryl-3-morpholinopropanones
AU2002352625A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
Zhao et al. Tri-ortho-cresyl phosphate (TOCP) decreases the levels of cytoskeletal proteins in hen sciatic nerve
JPH0813745B2 (ja) 有機化合物におけるまたは関する改良
US6489355B2 (en) Methods of inhibiting the effects of amyloidogenic proteins
WO2008021432A2 (fr) Compositions et méthodes de traitement d'états affectant le système nerveux
JPH11506414A (ja) フェノチアジン類および／またはチオキサンテン類を用いてアルツハイマー病を治療および／または予防する方法
JP4491229B2 (ja) ミトコンドリアを保護するための医薬を調製するためのチアゾール誘導体の使用
WO2000012093A1 (fr) Procede de traitement des maladies neurodegeneratives
JPH07133225A (ja) 毛様体筋緊張緩和剤
JPH1135479A (ja) 蛋白質ｐ８２をチロシンリン酸化することを特徴とする糖尿病治療方法および糖尿病治療剤
Figueras et al. Antipsychotic drugs
MXPA97003636A (en) Use of aril-morpholine-, tiomorfolino- or piperacino-propanones replaced for the treatment to prevent alzhei disease
AU2007202612A1 (en) Use of thiazole derivatives for preparing a medicament intended to protect the mitochondria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2196529

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1996 507474

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019970700943

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1995929441

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995929441

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970700943

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1995929441

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019970700943

Country of ref document: KR